All Pharma News
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study

Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study
GLOBENEWSWIRE
18 Jan 2024
Share Share
Elevar Therapeutics Names Brian Cunningham Vice President of Sales

Elevar Therapeutics Names Brian Cunningham Vice President of Sales
GLOBENEWSWIRE
23 Oct 2023
Share Share
Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab

Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
GLOBENEWSWIRE
17 Oct 2023
Share Share
Hengrui, Elevar strike $600M marketing deal for liver cancer med

Hengrui, Elevar strike $600M marketing deal for liver cancer med
Fraiser Kansteiner FIERCE PHARMA
17 Oct 2023
Share Share
Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference

Elevar Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
GLOBENEWSWIRE
21 Sep 2023
Share Share
Elevar Therapeutics Joins Benefactors Council of Blue Faery

Elevar Therapeutics Joins Benefactors Council of Blue Faery
GLOBENEWSWIRE
19 Sep 2023
Share Share
Elevar Names Dr. Chris Galloway Vice President of Clinical Development

Elevar Names Dr. Chris Galloway Vice President of Clinical Development
GLOBENEWSWIRE
15 Aug 2023
Share Share
Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib

Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib
GLOBENEWSWIRE
03 Aug 2023
Share Share
Elevar Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Elevar Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
GLOBENEWSWIRE
24 Jul 2023
Share Share
Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab

Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
GLOBENEWSWIRE
17 Jul 2023
Share Share